These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24925887)

  • 1. Tests for equivalence of two survival functions: Alternative to the tests under proportional hazards.
    Martinez EE; Sinha D; Wang W; Lipsitz SR; Chappell RJ
    Stat Methods Med Res; 2017 Feb; 26(1):75-87. PubMed ID: 24925887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tests for equivalence of two survival functions: alternatives to the PH and PO models.
    Shen PS
    J Biopharm Stat; 2021 Jan; 31(1):79-90. PubMed ID: 32663108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
    Möllenhoff K; Tresch A
    Lifetime Data Anal; 2023 Jul; 29(3):483-507. PubMed ID: 36708450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing equivalence of survival before but not after end of follow-up.
    Furberg JK; Pipper CB; Scheike T
    Lifetime Data Anal; 2021 Apr; 27(2):216-243. PubMed ID: 33515387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma.
    Com-Nougue C; Rodary C; Patte C
    Stat Med; 1993 Jul; 12(14):1353-64. PubMed ID: 8210831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are restricted mean survival time methods especially useful for noninferiority trials?
    Freidlin B; Hu C; Korn EL
    Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method.
    Kimura R; Nomura S; Nagashima K; Sato Y
    BMC Med Res Methodol; 2024 Jul; 24(1):166. PubMed ID: 39080523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence tests before end of follow-up under the class of log transformation model.
    Shen PS
    J Biopharm Stat; 2023 May; 33(3):324-334. PubMed ID: 36484478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimality of testing procedures for survival data in the nonproportional hazards setting.
    Arfè A; Alexander B; Trippa L
    Biometrics; 2021 Jun; 77(2):587-598. PubMed ID: 32535892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A log-rank test for equivalence of two survivor functions.
    Wellek S
    Biometrics; 1993 Sep; 49(3):877-81. PubMed ID: 8241376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of random survival forests in understanding the determinants of under-five child mortality in Uganda in the presence of covariates that satisfy the proportional and non-proportional hazards assumption.
    Nasejje JB; Mwambi H
    BMC Res Notes; 2017 Sep; 10(1):459. PubMed ID: 28882171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A win ratio approach for comparing crossing survival curves in clinical trials.
    Zheng S; Wang D; Qiu J; Chen T; Gamalo M
    J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalence tests under the Cox-Aalen model and the partly Aalen model.
    Shen PS
    J Biopharm Stat; 2022 Sep; 32(5):789-801. PubMed ID: 35171755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
    Yang S; Ambrosius WT; Fine LJ; Bress AP; Cushman WC; Raj DS; Rehman S; Tamariz L
    Clin Trials; 2018 Jun; 15(3):305-312. PubMed ID: 29671345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time.
    Akazawa K; Nakamura T; Moriguchi S; Shimada M; Nose Y
    Comput Methods Programs Biomed; 1991 Jul; 35(3):203-12. PubMed ID: 1935013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.